Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

Company Overview

Aerovate Therapeutics, Inc. is a clinical‐stage biopharmaceutical company dedicated to developing inhaled therapies for serious respiratory diseases. The company leverages a proprietary aerosol delivery platform designed to optimize drug deposition in the lungs, enabling targeted treatment for conditions such as non–cystic fibrosis bronchiectasis, severe asthma and chronic obstructive pulmonary disease. Aerovate’s development pipeline includes multiple product candidates in various stages of clinical and preclinical research, all focused on improving therapeutic outcomes while minimizing systemic side effects commonly associated with oral or intravenous administration.

Founded in 2018 as a spin‐out from leading academic research programs in pulmonary medicine, Aerovate is headquartered in Boston, Massachusetts, with additional research facilities in the San Francisco Bay Area. The company has established strategic collaborations with academic institutions and contract research organizations across North America and Europe to advance its inhaled drug delivery technology. Aerovate’s R&D efforts center on harnessing novel small molecules and biologics, reformulated for inhalation, to treat both infectious and inflammatory lung conditions.

Aerovate’s leadership team is comprised of industry veterans with deep expertise in respiratory drug development and inhalation device engineering. Chief Executive Officer Dr. Jane Carter brings over 25 years of experience in biotech leadership, having previously held senior roles at global pharmaceutical companies. The company’s board includes experts in pulmonology, drug delivery science and regulatory affairs, guiding Aerovate through late‐stage clinical trials and toward commercialization.

Key Stats

• Today's Range: $9.36 to $9.70
• 50-Day Range: $6.76 to $11.14
• 52-Week Range: $56.35 to $105.00
• Volume: 222,632 shs
• Average Volume: 12,412 shs
• Market Capitalization: $274.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AVTE Stock Analysis - Frequently Asked Questions

How have AVTE shares performed this year?

Aerovate Therapeutics' stock was trading at $92.75 on January 1st, 2025. Since then, AVTE stock has decreased by 89.8% and is now trading at $9.47.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its quarterly earnings results on Friday, April, 25th. The company reported ($3.15) EPS for the quarter, beating the consensus estimate of ($10.50) by $7.35.

When did Aerovate Therapeutics' stock split?

Aerovate Therapeutics's stock reverse split on the morning of Tuesday, April 29th 2025.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Aerovate Therapeutics IPO?

Aerovate Therapeutics (AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aerovate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 4/25/2025
• Record date for 4/28 Dividend: 4/25/2025
• Dividend Payable: 4/28/2025
• Ex-Dividend for 4/28 Dividend: 4/29/2025
• Today: 7/20/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVTE
• CIK: 1798749
• Web: aerovatetx.com
• Phone: 617-443-2400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -90.19%
• Return on Assets: -77.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.78
• Quick Ratio: 8.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.96 per share
• Price / Book: 2.39

Miscellaneous

• Outstanding Shares: 28,985,000
• Free Float: 21,685,000
• Market Cap: $274.49 million
• Optionable: Optionable
• Beta: 0.95